Zurich (awp) – The biotechnology laboratory Idorsia announced on Wednesday that it had obtained approval from the United States Medicines Agency (FDA) for aprocitentan in the treatment of resistant high blood pressure in the United States.
Called Tryvio, it is the first oral antihypertensive treatment approved in almost 40 years. It will be made available to millions of American patients who are not treated with other drugs during the second half of the year, reports a press release.
Stefan Schneider, analyst at Vontobel, says he is waiting for the next statements from management, because “it will be interesting to learn why the launch does not start until the second half of the year and how they see the chances of success if the launch does not cannot be fully financially supported.
Last September, Idorsia bought the marketing rights for aprocitentan from Janssen Biotech, a subsidiary of the American giant Johnson & Johnson. Baader Helvea expert Leonildo Delgado expects Idorsia to find “a new, cash-rich partner for the global commercialization of Tryvio.”
Idorsia submitted an application for approval of this treatment to the European Medicines Agency (EMA) in early 2023.
After soaring by more than 17% shortly after the opening, Idorsia shares ended the session up 1.4% to 2.28 Swiss francs in a general SPI index up 0.33%.
ib/jh/ol/al